Starrels Joanna L, Peyser Deena, Haughton Lorlette, Fox Aaron, Merlin Jessica S, Arnsten Julia H, Cunningham Chinazo O
a Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York , USA.
b Center for Alcohol Studies , Rutgers University , New York , New York , USA.
Subst Abus. 2016;37(1):148-53. doi: 10.1080/08897077.2015.1129391.
Human immunodeficiency virus (HIV)-infected patients have a high prevalence of chronic pain and opioid use, making HIV care a critical setting for improving the safety of opioid prescribing. Little is known about HIV treatment providers' perspectives about opioid prescribing to patients with chronic pain.
The authors administered a questionnaire and conducted semistructured telephone interviews with 18 HIV treatment providers (infectious disease specialists, general internists, family medicine physicians, nurse practitioners, and physician assistants) in Bronx, NY. Open-ended interview questions focused on providers' experiences, beliefs, and attitudes about opioid prescribing and about the use of guideline-based opioid prescribing practices (conservative prescribing, and monitoring for and responding to misuse). Transcripts were thematically analyzed using a modified grounded theory approach.
Eighteen HIV treatment providers included 13 physicians, four nurse practitioners, and one physician assistant. They were 62% female, 56% white, and practiced as HIV treatment providers for a mean of 14.6 years. Most reported always or almost always using opioid treatment agreements (56%) and urine drug testing (61%) with their patients on long-term opioid therapy. HIV treatment providers tended to view opioid prescribing for chronic pain within the "HIV paradigm," a set of priorities and principles defined by three key themes: (1) primacy of HIV goals, (2) familiarity with substance use, and (3) the clinician as ally. The HIV paradigm sometimes supported, and sometimes conflicted with, guideline-based opioid prescribing practices. For HIV treatment providers, perceived alignment with the HIV paradigm determined whether and how guideline-based opioid prescribing practices were adopted. For example, the primacy of HIV goals superseded conservative opioid prescribing when providers prescribed opioids with the goal of retaining patients in HIV care.
These findings highlight unique factors in HIV care that influence adoption of guideline-based opioid prescribing practices. These factors should be considered in future research and initiatives to address opioid prescribing in HIV care.
感染人类免疫缺陷病毒(HIV)的患者慢性疼痛和使用阿片类药物的比例很高,这使得HIV护理成为提高阿片类药物处方安全性的关键领域。关于HIV治疗提供者对慢性疼痛患者开具阿片类药物的看法,我们知之甚少。
作者对纽约布朗克斯区的18名HIV治疗提供者(传染病专家、普通内科医生、家庭医学医生、执业护士和医师助理)进行了问卷调查并开展了半结构化电话访谈。开放式访谈问题聚焦于提供者对阿片类药物处方以及基于指南的阿片类药物处方实践(保守处方、监测和应对药物滥用)的经验、信念和态度。使用改良的扎根理论方法对访谈记录进行主题分析。
18名HIV治疗提供者包括13名医生、4名执业护士和1名医师助理。他们中62%为女性,56%为白人,平均担任HIV治疗提供者14.6年。大多数人报告称,在为长期接受阿片类药物治疗的患者治疗时,总是或几乎总是使用阿片类药物治疗协议(56%)和尿液药物检测(61%)。HIV治疗提供者倾向于在“HIV范式”内看待慢性疼痛的阿片类药物处方,“HIV范式”是由三个关键主题定义的一组优先事项和原则:(1)HIV目标的首要性,(2)对物质使用的熟悉程度,(3)临床医生作为盟友。HIV范式有时支持基于指南的阿片类药物处方实践,有时与之冲突。对于HIV治疗提供者来说,与HIV范式的认知一致性决定了是否以及如何采用基于指南的阿片类药物处方实践。例如,当提供者为了让患者继续接受HIV护理而开具阿片类药物时,HIV目标的首要性取代了保守的阿片类药物处方。
这些发现凸显了HIV护理中影响采用基于指南的阿片类药物处方实践的独特因素。在未来关于HIV护理中阿片类药物处方的研究和倡议中应考虑这些因素。